Pharmacokinetic properties of fentanyl effervescent buccal tablets: A phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers
Authors:
- Mona DarwishMDMona Darwish
- Mary KirbyMKMary Kirby
- Philmore RobertsonPRPhilmore Robertson
- William TracewellWTWilliam Tracewell
- John G. JiangJJJohn G. Jiang
- 1 May 2006
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (5) , 707-714
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Alternative Treatments of Breakthrough Pain in Patients Receiving Spinal Analgesics for Cancer PainJournal of Pain and Symptom Management, 2005
- FentanylJournal of Pain and Symptom Management, 2005
- Pharmacokinetics, safety and tolerability of a novel 100 ?g/h transdermal fentanyl patch co-administered with 100 mg oral naltrexone in healthy malesClinical Pharmacology & Therapeutics, 2005
- Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy VolunteersClinical Pharmacokinetics, 2005
- The role of oral transmucosal fentanyl citrate in the management of breakthrough cancer painInternational Journal of Palliative Nursing, 2002
- Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot studyPalliative Medicine, 2001
- Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)Pain, 2001
- Confidence Interval Criteria for Assessment of Dose ProportionalityPharmaceutical Research, 2000
- Transdermal fentanyl: Suggested recommendations for clinical useJournal of Pain and Symptom Management, 1992
- Tissue Redistribution of Fentanyl and Termination of Its Effects in RatsAnesthesiology, 1981